Kiril and Georgi Domuschiev invest an additional $5 million in the fight against malaria

Kiril and Georgi Domuschiev, owners of the Bulgarian company Huvepharma, will invest an additional 5 million dollars through their Domuschiev Impact fund for the creation of a Global Anti-Malaria Center that will serve the fight against this disease.

The center will develop and provide affordable anti-malarial drugs to regions heavily affected by the disease, as reported by Domuschiev Impact. This is the first commitment of the new charity, announced during the annual meeting of the Clinton Global Initiative (CGI), which took place in late September in New York. Since last year, Kiril Domuschiev has been a member of the CGI Advisory Board of the 42nd US President Bill Clinton’s foundation, along with other eminent world leaders.

Domuschiev Impact is a fund of the brothers Kiril and Georgi Domuschiev, which aims to drive global change through investments in science, innovation and people, facilitating sustainability in various sectors.

The organization, in collaboration with the Clinton Global Initiative and other similar platforms, will also invest in training small cooperatives and farmers in Africa to improve sustainable animal protein production. For 5 years, farmers will receive free livestock management expertise, nutrition support, veterinary services and essential animal health products from Huvepharma, with the goal to promote food security and prosperity in the region.

Domuschiev Impact's ambition is to invest an additional $5 million in the development of affordable malaria drugs. Securing a lower cost of the drugs will be possible through an integrated supply chain enabled by the manufacturing innovation and strength of Huevepharma and the personal philanthropic commitment of the Domuschievi family, as was emphasized by the Clinton Global Initiative.

Huevepharma's experienced R&D team will industrialize and produce an affordable anti-malarial drug without making any profit. This can only be realized thanks to the company's ability to vertically integrate the entire manufacturing and distribution process. This is what will ensure low prices and broad access to life-saving drugs in the most affected areas.

The action plan calls for an expansion of the anti-malaria research and development laboratory to begin by June 2025, with the first production lines to start operating in June 2026.

The areas of the world affected by malaria are constantly expanding, due to climate change, increased urbanization, migration and population growth, states the CGI . A cure for malaria could save millions of lives, but manufacturers currently rely on an unsustainable supply chain entirely dependent on a single plant species – Artesia anoi. It is grown in conflict areas, and is a subject to an unstable market and huge price fluctuations. The commercialization of a semi-synthetic substitute for Artesia Anoi is necessary to stabilize the supply chain, reduce cost differentials, and ensure that a sustainable, long-term malaria treatment regimen is available to the millions of people who need it.

To realize its goals in the fight against malaria, Domuschiev Impact will seek partnerships both within the CGI community and among other representatives of business and civil society organizations in order to secure co-investment and achieve greater impact.

Huvepharma is a company specializing in the production of human and animal healthcare products as well as nutritional supplements - distributed in over 100 countries. The company operates manufacturing facilities focused on biotechnology, vaccines and veterinary drugs in France, Italy, Bulgaria and the USA.